Bicycle Therapeutics (BCYC) reported third-quarter 2026 collaboration revenue of $34.1 million, compared with $11.7 million a year earlier. Net loss was $10.5 million, or $0.15 per basic and diluted share, compared with a $59.1 million loss, or $0.85 per share, in the prior-year quarter.
The company ended September with $469.9 million in cash and cash equivalents and said it expects its cash runway to extend into 2030. The FDA granted Orphan Drug Designation to nuzefatide pevedotin for pancreatic cancer.
- Third-quarter R&D expense was $33.4 million, down from $58.4 million a year earlier.
- G&A expense was $14.1 million, down from $18.9 million.
- Bicycle expects further nuzefatide updates in 2027.
- The first company-sponsored radioligand clinical trial for BT1702 is expected to begin in the second half of 2027.
$BCYC Insider Trading Activity
$BCYC insiders have traded $BCYC stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.
Here’s a breakdown of recent trading of $BCYC stock by insiders over the last 6 months:
- KEVIN LEE (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 4 sales selling 15,447 shares for an estimated $59,947.
- MICHAEL SKYNNER (CHIEF SCIENTIFIC OFFICER) has made 0 purchases and 4 sales selling 4,836 shares for an estimated $18,765.
- MICHAEL CHARLES FERGUSON HANNAY (CHIEF PROD & SUPPLY CHAIN OFF) has made 0 purchases and 4 sales selling 3,575 shares for an estimated $13,848.
- ROBERT CHARLES SWANTON sold 3,431 shares for an estimated $11,905
- JENNIFER SCOTT PERRY (Chief Operating Officer) has made 0 purchases and 6 sales selling 2,912 shares for an estimated $11,367.
- TRAVIS ALVIN THOMPSON (Chief Financial Officer) has made 0 purchases and 4 sales selling 1,895 shares for an estimated $7,326.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BCYC Hedge Fund Activity
We have seen 50 institutional investors add shares of $BCYC stock to their portfolio, and 30 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIREN, L.L.C. removed 1,560,882 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $6,618,139
- PRINCIPAL FINANCIAL GROUP INC removed 1,174,625 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $4,980,410
- RENAISSANCE TECHNOLOGIES LLC added 554,100 shares (+56.6%) to their portfolio in Q2 2026, for an estimated $2,349,384
- QUBE RESEARCH & TECHNOLOGIES LTD added 466,950 shares (+151.3%) to their portfolio in Q2 2026, for an estimated $1,979,868
- DIADEMA PARTNERS LP added 462,724 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,961,949
- SILVERCREST ASSET MANAGEMENT GROUP LLC removed 428,684 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $1,817,620
- MARSHALL WACE, LLP added 420,605 shares (+111.5%) to their portfolio in Q2 2026, for an estimated $1,783,365
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
